Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates The following represents disclosure information provided by authors of this ...
NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...
The epidermal growth factor receptor (EGFR) is a membrane-bound tyrosine kinase that integrates signals from multiple ligands to regulate vascular cell behaviour. Upon ligand engagement, EGFR ...
Clinical Trials Arena on MSN
First patient dosed in Racura’s HARNESS-1 trial of RC220
The first patient was treated at Monash Health in Clayton, Victoria, Australia, with other trial sites planned in the near ...
Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.
Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib ...
A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR ...
MIT researchers have demonstrated that cell membrane composition directly influences EGFR activity, with elevated negatively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results